Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Franco Sicuro

Psychiatry Olivette, MO Medical Doctor

NPI 1629159207 CMS profile 346593

10199 Woodfield Ln Ste 10, Olivette, MO 63132

Open in the dashboard

General payments

$16,762

266 records reported · program years 2019–2020

Research payments

$1,457

Paid to them · 10 records reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,282,960 paid to institutions, not to them · program years 2019–2022

Through program year 2020, Franco Sicuro of Olivette, MO is reported in the CMS Open Payments database as having received $16,762 across 266 general payments and $1,457 in research payments paid to them. Separately, studies naming them as principal investigator received $2,282,960 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $6,765 113
2019 General $9,997 153
2019 Research $1,457 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Franco Sicuro
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Franco Sicuro were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Franco Sicuro Psychiatry median Middle half National median
2019 $9,997 $184 $59–$605 $163
2020 $6,765 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Allergan Inc. $11,766 48 payments
  2. Avanir Pharmaceuticals, Inc. $1,146 10 payments
  3. Sunovion Pharmaceuticals Inc. $631 35 payments
  4. Janssen Pharmaceuticals, Inc $536 25 payments
  5. Otsuka America Pharmaceutical, Inc. $395 27 payments
  6. Vanda Pharmaceuticals Inc. $374 20 payments
  7. Teva Pharmaceuticals USA, Inc. $336 18 payments
  8. Validus Pharmaceuticals LLC $220 16 payments
  9. Alkermes, Inc. $217 12 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $214 2 payments
  11. Other $927 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,000 6 payments
  2. Food and Beverage $4,222 252 payments
  3. Travel and Lodging $1,349 5 payments
  4. Education $190 3 payments
Products named General payments · program years 2019–2020
  1. VRAYLAR $11,717 47 payments
  2. LATUDA $631 35 payments
  3. SPRAVATO $480 17 payments
  4. HETLIOZ $374 20 payments
  5. FANAPT $374 20 payments
  6. INVEGA SUSTENNA $259 14 payments
  7. AUSTEDO $235 17 payments
  8. REXULTI $231 16 payments
  9. Equetro $220 16 payments
  10. ARISTADA INITIO $180 10 payments
  11. Other $1,910 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2020
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,457 10 payments

Records

276 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record